Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/1996
03/27/1996EP0702962A2 Preparations for inhibiting mammalian breast carcinoma with tamoxifen and analogs thereof, and certain naphthyl compounds
03/27/1996EP0702961A2 Compositions for minimizing the uterotrophic effect of tamoxifen and its analogs
03/27/1996EP0702951A1 Use of a NO-synthetase inhibitor as medicament for reducing alcohol consumption or for preventing excessive alcohol consumption
03/27/1996EP0702566A1 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
03/27/1996EP0702555A1 Pyrazolopyrimidinones for the treatment of impotence
03/27/1996EP0702554A1 Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
03/27/1996EP0702518A1 Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
03/26/1996US5502058 Lidocaine and dextromethorphan or dextrophan
03/26/1996US5502052 Use of a combination of apraclonidine and timolol to control intraocular pressure
03/26/1996US5502050 Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
03/26/1996US5502040 Anticoccidial method
03/26/1996US5501861 Carbohydrates
03/26/1996US5501856 Controlled-release pharmaceutical preparation for intra-ocular implant
03/23/1996CA2132690A1 Control and modulation of inflammatory response in humans in need of such control and modulation
03/21/1996WO1996008561A1 Method for detection of malfolded protein
03/21/1996WO1996008557A1 Human inositol monophosphatase h1
03/21/1996WO1996008515A1 Anti-receptor and growth blocking agents to the vitamin b12/transcobalamin ii receptor and binding sites
03/21/1996WO1996008510A1 Hu-B1.219, A NOVEL HUMAN HEMATOPOIETIN RECEPTOR
03/21/1996WO1996008487A1 Endothelin antagonists bearing pyridyl amides
03/21/1996WO1996008272A1 Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
03/21/1996WO1996008271A1 Protection of hemopoietic cells during chemotherapy or radiotherapy
03/21/1996WO1996008268A1 Inhibition of endothelin-1 to reduce inflammatory processes
03/21/1996WO1996008263A1 Intracellular delivery of chemical agents to a specific cell type
03/21/1996WO1996008248A1 Compositions for the treatment of skin disorders
03/21/1996WO1996008241A1 Anaesthetic analgesic gas mixtures containing enflurane or isoflurane in combination with sevoflurane or desflurane
03/21/1996WO1996008238A1 Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists
03/21/1996CA2199939A1 Inhibition of endothelin-1 to reduce inflammatory processes
03/21/1996CA2199730A1 Protection of hemopoietic cells during chemotherapy or radiotherapy
03/21/1996CA2199048A1 Anaesthetic analgesic gas mixtures containing enflurane or isoflurane in combination with sevoflurane or desflurane
03/21/1996CA2198361A1 Intracellular delivery of chemical agents to a specific cell type
03/21/1996CA2198263A1 Method for detection of malfolded protein
03/20/1996EP0701819A2 Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
03/20/1996EP0701814A2 Cosmetic or dermatologic composition containing hydrophobised inorganic pigment to maintain the amount of the skin urocanic acid
03/20/1996EP0701611A1 Human metabotropic glutamate receptors, nucleic acids encoding same and uses thereof
03/20/1996EP0701443A1 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
03/20/1996EP0701441A1 Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
03/20/1996EP0701438A1 Gaba-ergic modulation of eye growth
03/20/1996EP0701434A1 Preparations containing silicon dioxide to improve the taste thereof
03/20/1996CN1118989A Pharmaceutical compositions comprising paracetamol and L-cysteine or a precursor thereof
03/19/1996US5500434 Mixture of trandolapril and felodipine
03/19/1996US5500420 Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
03/14/1996WO1996007426A1 Enteral vaccine for vaginal infections
03/14/1996WO1996007418A1 Phosphonates and parathyroid hormone for osteoporosis
03/14/1996WO1996007417A1 Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
03/14/1996WO1996007412A1 Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer
03/14/1996WO1996007322A1 Method of sensitizing tumor cells with adenovirus e1a
03/14/1996CA2199265A1 Method of sensitizing tumor cells with adenovirus e1a
03/14/1996CA2199255A1 Enteral vaccine for vaginal infections
03/14/1996CA2199252A1 Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
03/14/1996CA2199251A1 Phosphonates and parathyroid hormone for osteoporosis
03/14/1996CA2197463A1 Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer
03/13/1996EP0700304A1 Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
03/13/1996EP0700288A1 Inhibition of hair growth
03/13/1996EP0700286A1 Apoptosis inhibitors for treating neurodegenerative diseases
03/13/1996EP0700282A1 Inhibition of hair growth
03/13/1996EP0690841A4 Synthetic matrix metalloprotease inhibitors and uses thereof
03/13/1996EP0500905B1 Pharmaceutical compositions for use in treating aids
03/13/1996EP0491007B1 Structural alterations of the egf receptor gene in human gliomas
03/13/1996EP0489108B1 Use of spiperone derivatives for immunosuppression
03/13/1996EP0439513B1 Composition for inhibiting transmission of aids
03/13/1996EP0438497B1 Vasopermeability-enhancing conjugates
03/07/1996WO1996006863A1 Agents for inducing apoptosis and applications of said agents in therapy
03/07/1996WO1996006640A1 Bioadhesive-wound healing composition
03/07/1996WO1996006639A2 Novel drugs containing chelate-forming agents
03/07/1996WO1996006622A1 Hyaluronic acid and derivatives for modulation of cellular activity
03/07/1996WO1996006614A1 Novel antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
03/07/1996WO1996006599A1 Taste-making lipid-based liquid medicinal composition
03/07/1996WO1996003515A3 Surface expression of enzyme in gene directed prodrug therapy
03/07/1996CA2198739A1 Novel antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
03/07/1996CA2194876A1 Bioadhesive-wound healing composition
03/06/1996EP0699444A2 Composition for the treatment of intestinal wounds or ulcers containing proteins, carbohydrates and fat
03/06/1996EP0699439A2 Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
03/06/1996EP0699438A2 Use of neurotensin antagonists for the preparation of diuretic drugs
03/06/1996EP0699432A1 Cosmetic and/or dermatologic composition containing thermal or mineral water and an active agent against acnee or ageing
03/06/1996EP0699202A1 Calanolide and related antiviral compounds, compositions, and uses thereof
03/06/1996EP0699079A1 Bioactive and/or targeted dendrimer conjugates
03/06/1996CN1118139A Fibrinogen receptor antagonists
03/06/1996CN1117874A Nasally administrable compositions
03/05/1996US5496827 Compositions for the transdermal delivery of nutrients
03/05/1996US5496803 Administering prolactin by itself or with a glucosteroid such as cortisol
03/05/1996US5496567 Vitamin supplements
03/05/1996US5496556 Administering a steroid reductase inhibiting compound, an androstene derivative
03/05/1996US5496545 Phosphate-binding polymers for oral administration
03/05/1996US5496533 Rhenium complexes
02/1996
02/29/1996WO1996006176A1 Functional modified hsv1-tk
02/29/1996WO1996006169A1 Human chemokine beta-9
02/29/1996WO1996005863A1 Compounds, pharmaceutical composition and diagnostic device comprising same and their use
02/29/1996WO1996005845A2 Treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction
02/29/1996WO1996005839A1 2,3-dihydro-1-(2,2,2-trifluoroethyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
02/29/1996WO1996005838A2 Combined preparation for the therapy of immune diseases
02/29/1996WO1996005827A1 N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
02/29/1996WO1996005816A1 Treatment of animals
02/29/1996DE4430128A1 Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen Combination with immunosuppressive drug, cardiovascular and cerebral effects
02/29/1996CA2198452A1 Treatment of animals
02/29/1996CA2198206A1 Human chemokine beta-9
02/29/1996CA2195973A1 N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
02/28/1996EP0698392A1 Compositions containing a RAR alpha specific ligand and at least one fatty acid
02/28/1996EP0697891A1 Polyoxime compounds and their preparation
02/28/1996EP0697874A1 Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor
02/28/1996EP0697870A1 Btp receptor modulator of the gaba a?/chloride channel complex for prolonging the duration of the gaba induced membrane current
1 ... 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 ... 1151